Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 8/20 | 0.44 |
| ▸ | CNR1 | P21554 | 7/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453001 | 0.89 | CNR2 (0.47) | CNR2CNR1HDAC3 | |
| SCHEMBL5448739 | 0.85 | ATM (0.52) | ATMCNR2CNR1HTR3AKDM4E | |
| SCHEMBL14463733 | 0.85 | ATM (0.56) | ATMCNR2CNR1HTR3A | |
| SCHEMBL5452543 | 0.84 | ATM (0.52) | ATMCNR2CNR1HTR3AKDM4E | |
| SCHEMBL5450078 | 0.84 | ATM (0.55) | ATMCNR2CNR1HTR3AKDM4E | |
| SCHEMBL5446808 | 0.78 | IDO1 (0.51) | ATMHRH3 | |
| SCHEMBL5441614 | 0.78 | ATM (0.48) | ATMCNR2CNR1S1PR1HTR3A | |
| SCHEMBL5444219 | 0.78 | ATM (0.52) | ATMCNR2CNR1HTR3AKDM4E | |
| SCHEMBL5453959 | 0.78 | ATM (0.63) | ATMCNR2CNR1HTR3AKDM4E | |
| SCHEMBL5451141 | 0.76 | ATM (0.50) | ATMCNR2CNR1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | ATM 4514/4885CNR2 106/4885CNR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.